193 related articles for article (PubMed ID: 23283526)
1. A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.
Johnston SR; Gómez H; Stemmer SM; Richie M; Durante M; Pandite L; Goodman V; Slamon D
Breast Cancer Res Treat; 2013 Feb; 137(3):755-66. PubMed ID: 23283526
[TBL] [Abstract][Full Text] [Related]
2. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN
J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
4. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
[TBL] [Abstract][Full Text] [Related]
5. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.
Boussen H; Cristofanilli M; Zaks T; DeSilvio M; Salazar V; Spector N
J Clin Oncol; 2010 Jul; 28(20):3248-55. PubMed ID: 20530274
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.
Cristofanilli M; Johnston SR; Manikhas A; Gomez HL; Gladkov O; Shao Z; Safina S; Blackwell KL; Alvarez RH; Rubin SD; Ranganathan S; Redhu S; Trudeau ME
Breast Cancer Res Treat; 2013 Jan; 137(2):471-82. PubMed ID: 23239151
[TBL] [Abstract][Full Text] [Related]
7. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
Guan Z; Xu B; DeSilvio ML; Shen Z; Arpornwirat W; Tong Z; Lorvidhaya V; Jiang Z; Yang J; Makhson A; Leung WL; Russo MW; Newstat B; Wang L; Chen G; Oliva C; Gomez H
J Clin Oncol; 2013 Jun; 31(16):1947-53. PubMed ID: 23509322
[TBL] [Abstract][Full Text] [Related]
9. An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.
Bonnefoi H; Zaman K; Debled M; Fiche M; Fournier M; Nobahar M; Pierga JY; Koch KM; Bartlett J; Zimmer A; Marreaud S; Bogaerts J; Cameron D
Eur J Cancer; 2013 Jan; 49(2):281-9. PubMed ID: 22999386
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
[TBL] [Abstract][Full Text] [Related]
11. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
Ryan Q; Ibrahim A; Cohen MH; Johnson J; Ko CW; Sridhara R; Justice R; Pazdur R
Oncologist; 2008 Oct; 13(10):1114-9. PubMed ID: 18849320
[TBL] [Abstract][Full Text] [Related]
12. Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.
Kaklamani VG; Siziopikou K; Scholtens D; Lacouture M; Gordon J; Uthe R; Meservey C; Hansen N; Khan SA; Jeruss JS; Bethke K; Cianfrocca M; Rosen S; Von Roenn J; Wayne J; Parimi V; Jovanovic B; Gradishar W
Breast Cancer Res Treat; 2012 Apr; 132(3):833-42. PubMed ID: 21359953
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.
Valachis A; Nearchou A; Lind P; Mauri D
Breast Cancer Res Treat; 2012 Oct; 135(3):655-62. PubMed ID: 22875745
[TBL] [Abstract][Full Text] [Related]
14. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Cameron D; Casey M; Press M; Lindquist D; Pienkowski T; Romieu CG; Chan S; Jagiello-Gruszfeld A; Kaufman B; Crown J; Chan A; Campone M; Viens P; Davidson N; Gorbounova V; Raats JI; Skarlos D; Newstat B; Roychowdhury D; Paoletti P; Oliva C; Rubin S; Stein S; Geyer CE
Breast Cancer Res Treat; 2008 Dec; 112(3):533-43. PubMed ID: 18188694
[TBL] [Abstract][Full Text] [Related]
15. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
Guarneri V; Frassoldati A; Bottini A; Cagossi K; Bisagni G; Sarti S; Ravaioli A; Cavanna L; Giardina G; Musolino A; Untch M; Orlando L; Artioli F; Boni C; Generali DG; Serra P; Bagnalasta M; Marini L; Piacentini F; D'Amico R; Conte P
J Clin Oncol; 2012 Jun; 30(16):1989-95. PubMed ID: 22493419
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
Henary H; George GC; Wheler J; Naing A; Piha-Paul S; Fu S; Mistry R; Zinner R; Kurzrock R; Hong DS
Cancer Chemother Pharmacol; 2015 Sep; 76(3):597-603. PubMed ID: 26210681
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
Reardon DA; Groves MD; Wen PY; Nabors L; Mikkelsen T; Rosenfeld S; Raizer J; Barriuso J; McLendon RE; Suttle AB; Ma B; Curtis CM; Dar MM; de Bono J
Clin Cancer Res; 2013 Feb; 19(4):900-8. PubMed ID: 23363814
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
